Company intelligence / Profile preview

Thunderbolt Pharma

San Francisco, California, USA

Ownership: Private
Development stage: Other

Overview

Thunderbolt Pharma developed AUR200 (formerly a BAFF/APRIL dual antagonist Fc-fusion protein), designed as an innovative biologic for B-cell mediated autoimmune and nephrology disorders; IND-enabling studies were ongoing and it had not entered clinical trials at time of acquisition

Therapeutic areas: ImmunologyNephrology
Modalities: ProteinRecombinant fusion proteinBiologic
Industry: Biotech

Partnerships

Vitesse BiologicsOriginal asset licensed/acquired from Astellas Pharma

Beyond the preview

Go deeper on Thunderbolt Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thunderbolt Pharma.

Explore the full profile